Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session.
News | Heart Valve Technology
Bicuspid Aortic TAVR May Create Huge Market For Transcatheter Valves

February 4, 2021 — Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the ...

Home February 04, 2021
Home
The Occlutech implantable Atrial Flow Regulator (AFR) maintains an interatrial shunt with a predetermined diameter allowing for controlled blood flow from the left to the right atrium enabling the left atrium to decompress and lower left atrial pressure. This reduced left atrial pressure reduces heart failure symptoms and improves exercise tolerance.
News | Heart Failure
Occlutech's Atrial Flow Regulator for Heart Failure Receives FDA Breakthrough Device Designation

January, 27, 2021 — The U.S. Food and Drug Administration (FDA) has granted Occlutech a Breakthrough Device designation ...

Home January 27, 2021
Home
A new CMS national coverage determination for reimbursement for MitraClip significantly expand access to transcatheter mitral valve repair procedures for secondary mitral regurgitation.
News | Heart Valve Technology
Medicare Expands Coverage for MitraClip in Heart Failure Patients

January 20, 2021 — The U.S. Centers for Medicare and Medicaid Services (CMS) revised its National Coverage Determination ...

Home January 20, 2021
Home
Medtronic Evolut TAVR Cleared in Canada for Both Bicuspid Valves in Intermediate or Greater Risk and for All Low Risk Patients for TAVR
News | Structural Heart
Canada Clears Medtronic Evolut TAVR for Both Bicuspid Valves and for All Low Risk Patients

January 11, 2021 — Medtronic has received a new expanded indication from Health Canada for its Evolut Transcatheter ...

Home January 11, 2021
Home
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F Products + Features GmbH TricValve Transcatheter Bicval Valves System. The system uses two self-expanding valves in the vena cava for the treatment of patients with hemodynamically relevant tricuspid insufficiency without the need to touch the native tricuspid valve. #TTVR
News | Structural Heart
FDA Grants Break Through Device Designation for TricValve Transcatheter Bicaval Valves System

January 6, 2021 — The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to P+F ...

Home January 06, 2021
Home
The most popular DAIC content in December 2020 included the Boston Scientific Lotus TAVR valve being taken off the market, CMS approving expanding coverage of LVADs for more Medicare patients and numerous COVID-19 related cardiology stories and videos.
Feature
Most Popular Cardiology Technology Content in December 2020

January 5, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home January 05, 2021
Home
First Patient Treated With Harpoon Transcatheter Mitral Valve Repair Device in U.S. Trial. #TMVR
News | Structural Heart
First Patient Treated With Harpoon Transcatheter Mitral Valve Repair Device in U.S. Trial 

December 29, 2020 — Edwards Lifesciences announced Dec. 21 that the first patient was treated in the RESTORE clinical ...

Home December 29, 2020
Home
Health Canada has approved the expanded use of the Edwards Lifesciences Sapien 3 and Sapien 3 Ultra transcatheter aortic valve replacement (TAVR) heart valves for the transfemoral treatment of patients diagnosed with severe symptomatic aortic stenosis who are at low risk for open-heart surgery. #TAVR #TAVI
News | Structural Heart
Edwards Sapien 3 TAVR Valve Receives Expanded Approval in Canada

December 29, 2020 — Health Canada has approved the expanded use of the Edwards Lifesciences Sapien 3 and Sapien 3 Ultra ...

Home December 29, 2020
Home
COVID-19 related topics by far out-paced all other topics in cardiology in 2020 on the DAIC website. Several stories topped the list related to the cardiovascular issues with hydroxychloroquine being used as a treatment for the virus. Top new device technologies in 2020 included European approval of the Abbott Tendyne transcatheter mitral valve, FDA approval of Medtronic's new Micra AV pill-sized pacemaker, and FDA clearance of the first drug-eluting stent with short-duration dual-antiplatelet therapy.
Feature | Dave Fornell, Editor
Top 25 Stories in Cardiology in 2020

Here are the top 25 best performing articles on the Diagnostic and Interventional Cardiology (DAIC) website from 2020 ...

Home December 28, 2020
Home
This year's top videos are dominated by COVID-19's impact on cardiology and many of the videos from a series produced this year on Tuft Medical Center's cardiology program. Top DAIC cardiology videos from 2020 #TuftsmedicalCenter #Tufts #COVID19
Feature | Dave Fornell, Editor
Top 25 Cardiology Videos on DAIC in 2020

Here are the top performing 25 videos on the DAIC website in 2020. The picks are based on Google Analytics of the DAIC ...

Home December 23, 2020
Home
Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) so the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.
News | Heart Valve Technology
Foldax to Initiate FDA Clinical Study of Biopolymer Mitral Heart Valve

December 14, 2020 - Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an ...

Home December 14, 2020
Home
COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States. #DAIC
Feature | Cardiovascular Business | Dave Fornell, Editor
Most Popular Cardiology Technology Content in November 2020

December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home December 01, 2020
Home
A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve repair (TMVR) with use of the Baylis VersaCross RF Transseptal Solution, reporting guide delivery from femoral access in under 7.5 minutes.
News | Hemodynamic Monitoring Systems
Study Finds TMVR Procedural Efficiency Using the VersaCross RF Transseptal Solution

December 1, 2020 — A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve ...

Home December 01, 2020
Home
RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm
News
Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF

November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial ...

Home November 18, 2020
Home
Feature | Heart Valve Technology
TAVR Is Now Dominant Form of Aortic Valve Replacement in the United States

November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more ...

Home November 17, 2020
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now